Side-by-side comparison of AI visibility scores, market position, and capabilities
Vial is a tech-enabled CRO that converts dermatology and ophthalmology clinics into research sites, handling regulatory administration, equipment provisioning, and patient recruitment; raised $77M Series B in 2022;
Vial is a clinical research organization (CRO) founded in 2020 by Simon Burns and Jason Wang and headquartered in San Francisco, California. The company has built a technology-enabled model for running clinical trials that differs from traditional CROs by directly partnering with clinical practices — particularly in dermatology and ophthalmology — and converting them into research sites. Vial handles the full operational burden: regulatory and IRB submissions, site staff training, clinical equipment provisioning, electronic data capture (EDC) setup, and patient recruitment and scheduling. This allows clinics with no prior research experience to participate in trials, dramatically expanding the pool of available sites and accelerating patient enrollment timelines.
Pioneering organ-on-chip platform installed in 150+ labs including 17 of the top 25 biopharma companies; launched AVA™ high-throughput 96-chip system in 2025 and holds the only FDA ISTAND-accepted DILI Organ-Chip.
Emulate, Inc. is a Boston-based biotechnology company that designs, manufactures, and commercializes Organ-Chip technology — micro-engineered devices lined with living human cells that replicate the microstructure and function of human organs. Founded in 2013 as a spin-out from the Wyss Institute at Harvard University, Emulate's chips model the liver, intestine, lung, kidney, brain, and other organ systems with a fidelity that animal models and traditional cell culture cannot match. The technology was originally developed to reduce drug development attrition rates caused by poor translation from animal studies to human clinical outcomes.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.